salicylsalicylic acid and Tinnitus

salicylsalicylic acid has been researched along with Tinnitus in 1 studies

salicylsalicylic acid: structure
salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.

Tinnitus: A nonspecific symptom of hearing disorder characterized by the sensation of buzzing, ringing, clicking, pulsations, and other noises in the ear. Objective tinnitus refers to noises generated from within the ear or adjacent structures that can be heard by other individuals. The term subjective tinnitus is used when the sound is audible only to the affected individual. Tinnitus may occur as a manifestation of COCHLEAR DISEASES; VESTIBULOCOCHLEAR NERVE DISEASES; INTRACRANIAL HYPERTENSION; CRANIOCEREBRAL TRAUMA; and other conditions.

Research

Studies (1)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Brachial Artery Flow-mediated Dilation (FMD)

Endothelial function (NCT01775865)
Timeframe: Change from baseline brachial artery FMD at 4 weeks

Carotid-femoral Pulse Wave Velocity (CFPWV)

Aortic stiffness (NCT01775865)
Timeframe: Change in CFPWV from baseline at 4 weeks

Change in Cholesterol

secondary (NCT00624923)
Timeframe: Baseline to 30 mo

Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT

Secondary outcome, change in liver inflammation associated with NASH: ALT (NCT00624923)
Timeframe: baseline to 30 mo

Change in Inflammation Marker: CRP

Secondary outcome of change in inflammation marker CRP (NCT00624923)
Timeframe: baseline to 30 mo

Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months

(NCT00624923)
Timeframe: Baseline to 30 months

Change From Baseline in Fasting Glucose Over Time.

(NCT00799643)
Timeframe: 48 weeks from baseline

The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.

HbA1c (%, percentage of HbA1c) change from baseline. (NCT00799643)
Timeframe: 48 weeks from baseline

Change From Baseline and Trends in Fasting Glucose Over Time

(NCT00392678)
Timeframe: 14 week

Change From Baseline in 14-week Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in insulin from Baseline to Week 14 in data table below. (NCT00392678)
Timeframe: Baseline, week 14

Change in HbA1c

Change from baseline to either 14 or 26 weeks, or last HbA1c measurement prior to rescue therapy (NCT00392678)
Timeframe: 14 week

Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1

The primary outcome for the TINSAL-T2D study is change in HbA1c level from baseline to week 14 (stage 1) in the intent-to-treat (ITT) population with last observation carried forward. (NCT00392678)
Timeframe: 14 week

Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in C-peptide from Baseline to Week 14 is in the data table below (NCT00392678)
Timeframe: Baseline, week 14

Safety and Tolerability

See adverse event module for details. Safety and tolerability of salsalate compared to placebo as assessed by adverse events. (NCT00392678)
Timeframe: 14 weeks

Change in Lipids

"Change in lipids (low-density lipoprotein cholesterol [LDL-C], non-high-density lipoprotein cholesterol [non-HDL-C], triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL C], TC/HDL-C ratio, and LDL-C/HDL-C ratio)~LDL-C/HDL-C ratio not calculated" (NCT00392678)
Timeframe: 14 week

Trials

1 trial available for salicylsalicylic acid and Tinnitus